CORDIS - Resultados de investigaciones de la UE
CORDIS

CARdiomyopathy in type 2 DIAbetes mellitus

Descripción del proyecto

Datos masivos y biobancos para diagnósticar y tratar mejor enfermedades cardíacas en diabéticos

La prevalencia de la diabetes de tipo 2 ha alcanzado escala de pandemia.Los afectados corren un riesgo mayor de desarrollar cardiomiopatías, una enfermedad del músculo cardíaco que dificulta el bombeo de la sangre del corazón. Además, la insuficiencia cardíaca es una de las principales causas de muerte en este grupo. Si bien la cardiomiopatía diabética (CMD) se ha reconocido como condición clínica diferente, no se sabe con certeza si la CMD, en realidad, tiene un desarrollo y progresión de la enfermedad distintos en comparación con la cardiomiopatía convencional. La iniciativa CARDIATEAM pretende despejar esta duda comparando a los pacientes con diabetes e insuficiencia cardíaca con controles sanos. Encontrar biomarcadores de la CMD, a la vez que se desarrollan simultáneamente técnicas de tratamiento de datos masivos para identificar los grupos de riesgo basándose en diferencias fenotípicas, debería fomentar el diagnóstico precoz y un tratamiento con resultados mejores.

Objetivo

A rapidly evolving epidemic in Type 2 Diabetes (T2DM) is afflicting all ages, sexes and socioeconomic classes which includes serious comorbidities such as heart diseases. While ischaemic heart disease represents the major cause of death of T2DM patients, heart failure (80% of Heart Failure with preserved Ejection Fraction) is the second most common cardiovascular disease in T2DM patients. The aim of CARDIATEAM is to determine whether T2DM represents a central mechanism contributing to the pathogenesis and progression of a specific cardiomyopathy, called “diabetic cardiomyopathy” (DCM), assessing whether DCM is unique and distinct from the other forms of heart failure.
To achieve this aim CARDIATEAM will build up a deeply phenotyped cohort, including an innovative imaging protocol, based on privileged access within the CARDIATEAM to already existing highly pertinent cohorts of diabetes and heart failure patients and control groups. Central biobanking of the cohort samples will allow detailed omics analysis that will feed together with the phenotype and imaging data into the central CARDIATEAM database. The data gathered will enable unsupervised machine-learning for clustering this heterogeneous population on phenotypic differences beyond diabetes. State-of-the-art big-data processing techniques and disease modeling will allow for controlling for common confounders such as BMI, smoking, age and blood pressure and will finally lead to the identification of new imaging and molecular biomarkers as well as understanding the taxonomy of the development and progression of DCM. Tailored preclinical models will be developed to explore the identified pathways revealing new therapeutic targets.
The results of CARDIATEAM will be able to impact clinical care with the stratification of patients into risk groups of developing DCM, earlier diagnosis of DCM and an improvement of therapy thanks to better assessment of underlying pathophysiology and identification of new biomarkers.

Régimen de financiación

RIA - Research and Innovation action

Coordinador

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Aportación neta de la UEn
€ 1 053 229,18
Dirección
RUE DE TOLBIAC 101
75654 Paris
Francia

Ver en el mapa

Región
Ile-de-France Ile-de-France Paris
Tipo de actividad
Research Organisations
Enlaces
Coste total
€ 2 923 240,30

Participantes (31)